The 12-digit NDC transition will succeed only when manufacturers, distributors, pharmacies, providers, payers, technology companies, and standards organizations can operate from compatible assumptions.
Consider a pharmaceutical manufacturer that has completed the required 12-digit National Drug Code (NDC) changes. It has updated systems, prepared packaging, and verified the accuracy of its product data. The transition can still fail if the distributor uses different identifier rules, the pharmacy cannot reconcile the package identifier with its system, the clinic’s electronic prescribing system has not adopted compatible requirements, or the health plan cannot process the related claim.
The manufacturer is ready, yet the end-to-end process still fails.
This scenario illustrates a central challenge for the healthcare industry: organizational readiness and ecosystem readiness are different outcomes. A company can complete its internal work and still encounter failures at the points where systems, products, and transactions cross organizational boundaries.
Thousands of interconnected systems, hundreds of affected business processes, and implementation work across nearly every part of healthcare make that distinction critical to a successful transition.
Why the 12-Digit NDC Transition Requires Cross-Industry Coordination
In March 2026, the Food and Drug Administration finalized the NDC Format and Barcoding Rule. The rule establishes a uniform 12-digit NDC format, replacing the existing variable-length 10-digit configurations. The new format takes effect March 7, 2033, followed by a three-year labeling transition period. Learn more about the NDC Format and Barcoding Rule at https://ndcforum.org/resources#rule-overview.
The NDC is one of the most widely used drug identifiers in healthcare. It appears in pharmaceutical manufacturing, packaging, distribution, inventory, prescribing, dispensing, claims, reimbursement, public health, safety reporting, regulatory reporting, and many other workflows. Because the identifier crosses so many systems, the transition requires shared definitions, coordinated timelines, and tested handoffs.
Where NDC Transition Risk Appears Between Organizations
Most organizations will begin by assessing their own systems and operations. They will identify affected applications, evaluate vendor requirements, develop budgets, and establish implementation timelines. Those internal plans also need to account for the organizations and systems that exchange NDC data with them.
Manufacturers and distributors: Manufacturers must determine how to represent NDCs in product data, packaging, labeling, and commercial systems. Distributors must receive, store, scan, and exchange those identifiers. Shared rules for product data, barcode application, and cutover timing will help protect product identification and inventory workflows.
Pharmacies, PBMs, and payers: Pharmacy systems must communicate with claims processors, switches, PBMs, and health plans. The rule changes the FDA-assigned NDC, while the existing HIPAA 11-digit reimbursement representation remains a separate consideration that still must be addressed by the Centers for Medicare & Medicaid Services (CMS). Organizations need a coordinated approach for managing these representations across claims and reimbursement workflows.
Technology vendors and their customers: Drug compendia, pharmacy management systems, EHRs, automation providers, and other technology companies support thousands of organizations. A vendor decision about data models, interfaces, or conversion logic can affect customers across multiple sectors, so vendor roadmaps and customer requirements need to remain visible to one another.
In each case, an organization can complete its internal work and still face operational problems when another part of the ecosystem uses different assumptions.
A major risk is fragmented preparation. Organizations may complete their own plans without sufficient visibility into the decisions, dependencies, and timelines of their partners.
Why Early NDC Decisions Matter
March 2033 may seem distant, but many implementation decisions need to begin years before the regulatory milestone.
Manufacturers may need to make packaging and barcode investments years before the transition. Technology vendors must establish product requirements and development schedules. Health plans and pharmacy systems must understand how transaction standards and identifier mappings will affect their applications.
Delayed or inconsistent decisions can compress testing schedules, create duplicative development, and lead to costly rework.
No single organization controls the full NDC workflow. Regulators establish requirements, standards organizations develop technical specifications, industry associations coordinate sector-specific activities, and individual companies implement changes within their own environments. Coordination is the mechanism that connects those responsibilities.
How the NDC Forum Supports Ecosystem Readiness
The NDC Coordination and Implementation Forum brings together manufacturers, distributors, pharmacies, providers, payers, technology companies, standards organizations, trade associations, government agencies, and other stakeholders. Together, participants coordinate the planning, dependencies, testing, and implementation required for the 12-digit NDC transition.
The Forum connects those efforts through shared visibility, aligned priorities, and coordinated execution.
The Forum’s ecosystem-wide implementation roadmap provides a shared view of major milestones, dependencies, decision points, and readiness considerations. It helps organizations understand how their implementation plans connect to activities occurring elsewhere.
Quarterly Forums are the one-stop shop for participants to get direct updates from regulators, standards bodies, trade associations, and other key implementers. They provide early visibility into emerging decisions, timelines, risks, and coordination needs across the NDC transition.
Focused Strike Forces move beyond discussion to address specific cross-sector questions and develop practical outputs. The Forum's initial Strike Forces are focused on finalizing the implementation roadmap, understanding where physical labels and electronic data must align, and examining the implications of legacy-labeled products remaining in distribution beyond the labeling transition.
Over time, these activities can also support coordinated testing and piloting, helping organizations validate that their systems work across trading partner and sector boundaries.
What Organizations Can Do Now
The industry has a defined regulatory timeline and several years to prepare. Organizations can use that time to identify dependencies early, coordinate decisions, share implementation experience, and reduce avoidable disruption.
Organizations need visibility into what their vendors, customers, trading partners, and adjacent sectors are planning. They also need a forum for surfacing concerns early and addressing issues that cross organizational boundaries.
Organizations that engage early can help shape the approaches that will guide their implementation and gain visibility into developments across the broader ecosystem.
March 2033 is the regulatory milestone. The work that will determine whether the industry reaches it successfully is happening now.
Prepare your organization and help strengthen readiness across the healthcare ecosystem. Patients, providers, and trading partners all depend on a reliable transition.
Learn more about the NDC Coordination and Implementation Forum, become a member, and find opportunities to participate at https://ndcforum.org/get-involved.